ERBB2 and breast cancer: The phase III PATINA trial wants to investigate the advantage of combining palbociclib with trastuzumab with or without pertuzumab and ET maintenance therapy after induction therapy in the first-line setting for HR-positive/HER2-positive metastatic BC [78].